leisure time -WSS

leisure time

author：leisure time 2025-09-30 03:38:19 - browse：464

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

WSS

How housing is health care on Long Island

Wegovy trial has doctors encouraged over new possibilities

What to make of Biden’s latest efforts on cancer research

IRA could hurt research into orphan drugs for rare diseases

Private equity could exacerbate cardiology's overuse problem, experts fear

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

focus

leisure time

focus

Psychedelics group wrestles with new pharma identity

Anavex keeps shifting the goalposts in its clinical trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How medical schools plan to diversify without affirmative action

United colonoscopy coverage change 'may cost lives,' doctors say

Maui's cultural, historic landmarks damaged in the devastating wildfires

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Dobbs anniversary: the lost opportunity of abortion as health care

WATCH: Why do bright lights make us see spots?

hotspot

How medical schools plan to diversify without affirmative action

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Private equity could exacerbate cardiology's overuse problem, experts fear

Drastic changes should bring profitability, startup health insurers say

WATCH: Why do bright lights make us see spots?

What to know about Virgin Galactic's 1st mission taking paying customers to space

explore

entertainment

knowledge

entertainment